Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SOS1 | Q07889 | 7/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22607055 | 0.90 | MPO (0.46) | SOS1LMNAKDM4E | |
| SCHEMBL22607023 | 0.90 | SOS1 (0.49) | PTGS2SOS1LMNASMN1; SMN2 | |
| SCHEMBL22584717 | 0.88 | SOS1 (0.44) | SOS1LMNAKDM4E | |
| SCHEMBL22607144 | 0.86 | SOS1 (0.53) | PTGS2SOS1 | |
| SCHEMBL22607021 | 0.83 | SOS1 (0.46) | SOS1DRD4LMNAHTTALDH1A1 | |
| SCHEMBL22607056 | 0.82 | KDM4E (0.47) | SOS1DRD4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL22607057 | 0.82 | SOS1 (0.47) | SOS1DRD4LMNADRD2DRD3 | |
| SCHEMBL22607141 | 0.80 | SOS1 (0.51) | SOS1SMN1; SMN2 | |
| SCHEMBL22606587 | 0.78 | SOS1 (0.47) | SOS1DRD4LMNADRD2DRD3 | |
| SCHEMBL22584715 | 0.77 | SOS1 (0.46) | SOS1DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | ENHANCEDBIO, INC. (KR) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | NEDD4, PFDN1, PF4 | PTGS2 4582/4885SOS1 1806/4885DRD4 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.